IMMURON Goodwill and Intangible Assets 2018-2024 | IMRN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

IMMURON goodwill and intangible assets from 2018 to 2024. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

IMMURON goodwill and intangible assets from 2018 to 2024. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$245.5B
Amgen (AMGN)	$159.6B
Gilead Sciences (GILD)	$146.9B
Vertex Pharmaceuticals (VRTX)	$100.7B
Bristol Myers Squibb (BMY)	$98.6B
CSL (CSLLY)	$85.1B
GSK (GSK)	$80.3B
Regeneron Pharmaceuticals (REGN)	$61.5B
Alnylam Pharmaceuticals (ALNY)	$58.8B
Argenex SE (ARGX)	$40B
BioNTech SE (BNTX)	$27.3B
Insmed (INSM)	$27B
Royalty Pharma (RPRX)	$20.4B
Biogen (BIIB)	$20.3B
Incyte (INCY)	$17B
Illumina (ILMN)	$15.4B
Genmab (GNMSF)	$15.3B
Genmab (GMAB)	$15B
Ascendis Pharma (ASND)	$12.1B
BioMarin Pharmaceutical (BMRN)	$11B
QIAGEN (QGEN)	$11B
Moderna (MRNA)	$10.9B
Swedish Orphan Biovitrum (BIOVF)	$10.3B
Exelixis (EXEL)	$10.3B
Verona Pharma American Depositary Share (VRNA)	$9B
Exact Sciences (EXAS)	$8.6B
Bio-Techne Corp (TECH)	$8.4B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$8.1B
Halozyme Therapeutics (HALO)	$7.9B